Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Client Area Book a 7-day Readout
Scipio bioscience logo — Single-cell sequencing on every benchtop

Scipio bioscience

Single-cell sequencing on every benchtop

Founded 2017 France France 14 employees Convertible Note Total: $15.79M Biopharma, Biotechnology

General Information

Company Name Scipio bioscience
Founded Year 2017
Location France France
Employees 14
Industries Biopharma, Biotechnology
Funding Stage Convertible Note
Social

BounceWatch is an independent company data service, not affiliated with Scipio bioscience. To contact Scipio bioscience, visit scipio.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Scipio bioscience compare?

A PDF of Scipio bioscience and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Scipio bioscience soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Scipio bioscience

Scipio Bioscience was a biotech startup founded in 2017, headquartered in France, with a mission to enable researchers to delve into the molecular mechanisms of life for improved health and sustainability. Their flagship product, the Asteria benchtop kit, aimed to facilitate scRNA-seq sample preparation, while Cytonaut, their cloud-based data analysis software, targeted biologists and bioinformaticians. The company's focus on providing researchers with autonomy in exploring single-cell data represented a commitment to delivering high-quality results and authentic biological information. However, on 18/09/2024, Scipio Bioscience unfortunately had to cease its operations. Notably, Scipio Bioscience secured a €2.13M convertible note investment from the European Innovation Council on 28 July 2023. The company was incubated at the Paris Santé Cochin incubator, located within the Cochin Hospital in Paris. Despite its closure, the company's innovative approach to single-cell sequencing and its potential impact on disease understanding made it noteworthy in the biopharma and biotechnology industries.

Business keywords: Sample preparation, Single-cell studies, Benchtop kits, Sequencing applications, Transcriptomics, Clinical research, Basic research, Bioinformatics, Cloud-based data analysis software

Services & Products

Asteria™ benchtop kit for easy scRNA-seq sample preparation
Cytonaut™ cloud-based data analysis software for biologists and bioinformaticians

Target Customers

academic researchers translational clinicians biologists bioinformaticians biomedical researchers

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note €2.13M 1
European Innovation Council
European Innovation Council
28 Jul 2023
Grant €2.46M 1
European Innovation Council
European Innovation Council
23 Mar 2022
Venture Round $4.00M 1
European Innovation Council
European Innovation Council
23 Mar 2022
Series A €6.00M 5
Seventure Partners Verve Ventures MERL Ventures Fund
Seventure Partners, Verve Ventures +3
25 Feb 2020
Seed Round €1.20M 2
Seventure Partners
Seventure Partners, HTGF | High-Tech Gruenderfonds
14 Nov 2017

Scipio bioscience Alternatives & Competitors

View All Alternatives
Scipio bioscience vs
3D Genomics
3D Genomics United States

We work with you to design the study, build the best cell models and develop informative data analys...

1 employees
Biopharma, Biotechnology
Scipio bioscience vs
The Bioinformatics CRO
The Bioinformatics CRO United States

Done Right, Now

18 employees
Biopharma, Biotechnology
Scipio bioscience vs
Oxford Nanopore Technologies
Oxford Nanopore Technologies United Kingdom

Our goal is to enable the analysis of anything, by anyone, anywhere.

Post-IPO Equity
1341 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Scipio bioscience

Single-cell sequencing on every benchtop
Scipio bioscience was founded in 2017.
Scipio bioscience is headquartered in France.
Scipio bioscience operates in Biopharma and Biotechnology. Its work centres on Sample preparation, Single-cell studies, Benchtop kits and Sequencing applications. Its customers include academic researchers, translational clinicians and biologists.
Scipio bioscience has approximately 14 employees.
Scipio bioscience has completed 5 funding rounds, raising a total of $15.79M. The latest funding stage is Convertible Note.
Scipio bioscience offers: Asteria™ benchtop kit for easy scRNA-seq sample preparation, Cytonaut™ cloud-based data analysis software for biologists and bioinformaticians.
Top alternatives and competitors to Scipio bioscience include 3D Genomics , The Bioinformatics CRO, Oxford Nanopore Technologies, Nodexus Inc., Polaris Biology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Scipio bioscience and 3D Genomics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Scipio bioscience, https://bouncewatch.com/company/scipio-bioscience, updated 11 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout